Mechanoenergetics characterizing oxygen wasting effect of caffeine in canine left ventricle. 2000

T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
National Cardiovascular Center, Suita, 565-8565 Japan.

Caffeine causes a considerable O(2) waste for positive inotropism in myocardium by complex pharmacological mechanisms. However, no quantitative study has yet characterized the mechanoenergetics of caffeine, particularly its O(2) cost of contractility in the E(max)-PVA-VO(2) framework. Here, E(max) is an index of ventricular contractility, PVA is a measure of total mechanical energy generated by ventricular contraction, and VO(2) is O(2) consumption of ventricular contraction. The E(max)-PVA-VO(2) framework proved to be powerful in cardiac mechanoenergetics. We therefore studied the effects of intracoronary caffeine at concentrations lower than 1 mmol/l on left ventricular (LV) E(max) and VO(2) for excitation-contraction (E-C) coupling in the excised cross-circulated canine heart. We enhanced LV E(max) by intracoronary infusion of caffeine after beta-blockade with propranolol and compared this effect with that of calcium. We obtained the relation between LV VO(2) and PVA with E(max) as a parameter. We then calculated the VO(2) for the E-C coupling by subtracting VO(2) under KCl arrest from the PVA-independent (or zero-PVA) VO(2) and the O(2) cost of E(max) as the slope of the E-C coupling VO(2)-E(max) relation. We found that this cost was 40% greater on average for caffeine than for calcium. This result, for the first time, characterized integratively cardiac mechanoenergetics of the O(2) wasting effect of the complex inotropic mechanisms of intracoronary caffeine at concentrations lower than 1 mmol/l in a beating whole heart.

UI MeSH Term Description Entries
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016276 Ventricular Function The hemodynamic and electrophysiological action of the HEART VENTRICLES. Function, Ventricular,Functions, Ventricular,Ventricular Functions
D016277 Ventricular Function, Left The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance. Left Ventricular Function,Function, Left Ventricular,Functions, Left Ventricular,Left Ventricular Functions,Ventricular Functions, Left

Related Publications

T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
July 1997, Anesthesiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
September 1994, Journal of molecular and cellular cardiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
October 1998, The Japanese journal of physiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
November 1990, The American journal of physiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
February 1982, Circulation research,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
January 2012, Acta medica Okayama,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
January 1988, The American journal of physiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
June 2004, The Japanese journal of physiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
June 1997, Anesthesiology,
T Takasago, and Y Goto, and K Hata, and A Saeki, and T Nishioka, and T W Taylor, and G Iribe, and S Mohri, and J Shimizu, and J Araki, and H Suga
March 1988, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!